With Tanel, Alan transforms Prosus's bet into its first African foothold

The essentials

Alan has finalized the acquisition of Tanel, a young health coverage platform operating in Senegal and Ivory Coast. Tanel brings approximately 70,000 people covered, more than 400 corporate clients, and a network of 1,200 pharmacies and providers. For Prosus, which committed €400 million to the €480 million funding round announced in June, the immediate issue is not Tanel's size. This is the first visible implementation of the promise associated with the funding: to help Alan expand into markets where Prosus already has experience, relationships and digital infrastructure.

Why Prosus Investors Should Look at a Small Senegalese Company

Alan is still a private equity firm, and Prosus's percentage stake is not disclosed. Tanel is much smaller than Alan, and the acquisition price remains unknown. Yet, this transaction goes to the heart of Prosus's model: allocating capital to technology platforms and then providing them with more than just a check to accelerate their development.

The potential value creation follows a precise chain. Prosus is financing Alan at a time when the company claims to exceed €800 million in annual recurring revenue. Alan is using some of its resources and expertise to enter a new continent through a local player. If this foothold allows the product to be replicated, the membership base to be expanded, and new services to be created, Alan's economic value can increase. Prosus benefits from this through its investment. If expansion absorbs capital without sustainably improving Alan's economy, the risk will flow back up the same path.

An acquisition planned since 2024

The transaction did not arise from an opportunistic encounter. Alan had participated in Tanel's seed funding in 2024. The teams therefore had approximately two years to observe the technology, the healthcare network, the customers, and the local execution capacity before bringing the two companies together. This reduces some of the information risk, without guaranteeing a successful integration.

Tanel was founded in 2021 with a simple proposition, difficult to formulate but difficult to execute: to make health insurance more accessible and transparent for businesses and their employees. The platform operates a network of over 1,200 pharmacies and providers and serves more than 400 companies. Alan thus acquires concrete connections with employers, healthcare facilities, and insured individuals, rather than an empty license in a new country.

The press release does not specify the price paid, the proportion of cash or securities, nor Tanel's revenues, losses, or retention rate. It does not allow for an assessment of the financial quality of the price. However, it does allow us to understand what is acquired: a local distribution network, contractual relationships, and a team-in other words, the time Alan would have had to spend rebuilding these assets from scratch.

Why Prosus Can Be Useful Beyond Capital

Prosus presented its investment in Alan as a way to support international expansion in regions where its group already has a presence. Africa is one of these territories. The holding company has extensive experience in payments, e-commerce, small businesses, and mobile usage through decades of activity and investment. Alan brings digital health insurance and a European interface. Alan brings the on-the-ground presence.

However, complementarity must be demonstrated, not just described. A seamless application does not eliminate local regulations, the fragmentation of providers, or differences in purchasing power. Health coverage is a financial and operational promise: when a member falls ill, the network must respond, the care process must be understood, and the payments must be properly managed.

Prosus's role can take several forms: access to technical talent, knowledge of local payment methods, commercial links with regional platforms, experience in fraud detection, and computing power for artificial intelligence tools. Alan and Prosus have not announced any quantified synergies on Tanel. This list therefore describes possibilities consistent with their statements, not gains already achieved.

A tempting calculation you shouldn't make

The real test: going from 70,000 to one million without losing the product's economic benefits

Alan aims to cover one million people in Africa by 2030. Based on Tanel's footprint, this represents a more than fourteenfold increase in four years. Part of this growth could come from expansion in Senegal and Ivory Coast; Alan also mentions plans to expand into French-speaking and then English-speaking markets in West and East Africa.

This ambition isn't simply about recruiting members. A healthcare platform must balance four dimensions: the price paid by companies or individuals, the frequency and cost of care, the quality of the network, and operating expenses. Growing too quickly in under-reimbursed populations can increase losses. Conversely, pooling product teams and technology across a broader base can improve efficiency.

Alan estimates that the health insurance markets in Senegal and Ivory Coast together represent approximately €600 million and are growing by nearly 10% annually. This is the company's estimate, useful as a rough guide but not supported by an independent study. Even if accurate, the existence of a market says nothing about the price at which Alan can target it or the sustainable market share.

From Tanel's member to Prosus's value

A test of Prosus's new discipline

Prosus wants to be judged on the profitability of its ecosystems and on a more transparent capital allocation. Alan is a significant investment: €400 million represents a real commitment, even at the holding company level. The acquisition of Tanel is happening quickly enough to demonstrate an intention to execute. It's happening too soon to prove that the return will materialize.

The timing is telling. Prosus announced the funding round in June. Alan finalized Tanel in early September. We can't infer that Prosus funds directly financed the transaction, as the precise use of the resources isn't detailed. We can see that both announcements reflect the same strategy: using digital health as an international platform, with particular support in markets already familiar to Prosus.

The main risk would be confusing geographic expansion with network effects. Healthcare data is sensitive, regulatory frameworks are national, and healthcare networks remain local. The software product can be shared; a large part of the implementation must be rebuilt country by country. Investors should therefore focus on the economic units, not just the number of flags added to the map.

What to watch for

Facts, reading, and unknowns